Amgen (AMGN)
(Delayed Data from NSDQ)
$321.91 USD
+0.12 (0.04%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $321.92 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$321.91 USD
+0.12 (0.04%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $321.92 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $227.84, marking a +0.18% move from the previous day.
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $227.66, moving +0.88% from the previous trading session.
Is Now the Right Time to Embrace Biotech ETFs?
by Yashwardhan Jain
Look if it's the right time to invest in biotech ETFs to help diversify your portfolio.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Amgen (AMGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $218.65, marking a -1.94% move from the previous day.
The Zacks Analyst Blog Highlights Apple, Verizon Communications, Amgen, Charles Schwab and The Cigna Group
by Zacks Equity Research
Apple, Verizon Communications, Amgen, Charles Schwab and The Cigna Group are part of the Zacks top Analyst Blog.
Top Analyst Reports for Apple, Verizon & Amgen
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Verizon Communications Inc. (VZ) and Amgen Inc. (AMGN).
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $222.02, marking a +0.39% move from the previous day.
Amgen (AMGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $227.11, moving -1.11% from the previous trading session.
Horizon's (HZNP) Tepezza Study in Japan for TED Meets Goal
by Zacks Equity Research
Horizon (HZNP) announces positive top-line results from its phase III study evaluating Tepezza for treating Thyroid Eye Disease with high disease activity in Japan.
Amgen's (AMGN) Blincyto sBLA Gets FDA Nod in Treating Leukemia
by Zacks Equity Research
Amgen (AMGN) announces full approval of its sBLA for Blincyto as an immune-oncology therapy for treating adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia.
Amgen (AMGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $229.66, marking a +0.53% move from the previous day.
AbbVie's (ABBV) Skyrizi Meets Ulcerative Colitis Study Goals
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi achieves statistical significance with its primary endpoint of clinical remission in a late-stage study as a maintenance treatment for ulcerative colitis.
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $218.82 in the latest trading session, marking a -0.88% move from the prior day.
The Zacks Analyst Blog Highlights JPMorgan Chase, McDonald's, Comcast, T-Mobile US and Amgen
by Zacks Equity Research
JPMorgan Chase, McDonald's, Comcast, T-Mobile US and Amgen are part of the Zacks top Analyst Blog.
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Top Analyst Reports for JPMorgan Chase, McDonald's & Comcast
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), McDonald's Corporation (MCD) and Comcast Corporation (CMCSA).
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Top Dividend Stocks to Maximize Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?